Truist Financial Corp Has $26.20 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Truist Financial Corp trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 107,448 shares of the medical instruments supplier’s stock after selling 16,171 shares during the quarter. Truist Financial Corp’s holdings in Becton, Dickinson and Company were worth $26,199,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Ontario Teachers Pension Plan Board boosted its holdings in Becton, Dickinson and Company by 242.8% during the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after acquiring an additional 1,263,391 shares during the period. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after acquiring an additional 516,427 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 11.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after acquiring an additional 512,566 shares during the period. Royal Bank of Canada boosted its holdings in Becton, Dickinson and Company by 28.5% during the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after acquiring an additional 473,914 shares during the period. Finally, Morgan Stanley boosted its holdings in Becton, Dickinson and Company by 4.5% during the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after acquiring an additional 435,168 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Raymond James upped their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Barclays increased their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Stock Up 0.8 %

NYSE BDX opened at $233.50 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm has a 50-day simple moving average of $239.10 and a 200 day simple moving average of $240.93. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The stock has a market cap of $67.46 billion, a PE ratio of 55.33, a PEG ratio of 1.91 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.98 earnings per share. On average, research analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.